ClinicalTrials.gg
Active, not recruitingNCT02399995Updated Apr 14, 2026

Health Related Quality of Life Following Hepatectomy for Colorectal Liver Metastasis: Global and Disease Specific Changes Over Time

An observational study in Colorectal Liver Metastasis, sponsored by Memorial Sloan Kettering Cancer Center. Active, not recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-14.

Sponsored by Memorial Sloan Kettering Cancer Center · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
219
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 61 studies in Neoplasm Metastasis by Memorial Sloan Kettering Cancer Center — 13 open to participants now, 27 under way, 1 of them phase 3. Neoplasm Metastasis · Memorial Sloan Kettering Cancer Center.

Started
2015
with 2 others
Observational
6 of 61
2 open now
Primary completion
2027-03
later than 5 of 26 live
Registered
32nd of 61
by date

Among the 61 studies in Neoplasm Metastasis by Memorial Sloan Kettering Cancer Center, this one is one of 3 that started in 2015, is one of 6 observational ones, reaches primary completion later than 5 of the 26 other live ones, and was the 32nd registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

13 of the 61 studies in Neoplasm Metastasis by Memorial Sloan Kettering Cancer Center are open now, in 1 country. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Neoplasm Metastasis by Memorial Sloan Kettering Cancer Center, or all of them as a file.
02

Study summary

This study is being done to learn more about health related quality of life factors in people having surgery for colorectal liver metastasis. The investigators will look at how these factors may change over time. The information gained from this study will help the investigators to understand the long-term effects that cancer treatments have on the health related quality of life of patients. This information is of high value and will help doctors talk to patients about the possible effects of their operations. While many patients live a long time after such operations, the studies that have been done do not tell the full story of what patients go through after surgery. This study will help us to understand cancer treatment from the patient's perspective. It will also help cancer patients make better decisions about their treatment options and will help them know what to expect after the operation.

03

Conditions studied

  • Colorectal Liver Metastasis

Browse trials for

Keywords

  • Quality of Life
  • Hepatectomy
  • 15-057
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients scheduled to undergo liver resection who meet the established criteria will be approached for participation in this study during their preoperative visit. Should patients not undergo their liver resection surgery within 30 days of consent they will be excluded and replaced. Patients undergoing a two stage resection will have their time point frozen for up to six months after their initial surgery. If the time before the second stage of their resection exceeds six months, these patients will be excluded and replaced. The time point will restart at the completion of the second time point. If the patient has an incomplete resection without mention of a second stage resection, the patient will be made ineligible, taken off study, and replaced.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Colorectal cancer liver (CRLM)
  • > 18 years of age
  • Absence of unresectable extrahepatic disease
  • No previous liver surgery for CRLM
  • Clinical risk score (CRS) >/= 3 or > 4 tumors
  • CRS includes the following variables;
  • Lymph node positive primary
  • Disease free interval \<12 months
  • CEA level >200ng/mL (highest CEA level within 6 months prior to surgery, not including day of surgery)
  • Tumor size > 5cm
  • Number of tumors >1(based on most recent scan or pathology before liver resection)
  • Each variable is given a score of one and summed to give final CRS
  • Clinical risk score (CRS) \< 3 with pending variables that cannot be determined preoperatively
  • If CRS is still \< 3 postoperatively, these patients will be excluded and replaced (inevaluable).
  • Ability to read and write in English
  • Undergoing liver resection/ ablation for CRLM
  • Underwent liver resection/ ablation for CRLM, but not their primary tumors

Exclusion criteria

Exclusion Criteria:

  • Non-English speaking
  • Inability to read and/or write
  • International Patients
  • Concurrent (excluding non-melanoma skin cancers)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
219 participants (actual)
Patient registry
No

Groups and cohorts

  • patients following hepatectomy

    Behavioral: HRQoL questionnaires.

Interventions

  • BehavioralHRQoL questionnaires.

    Questionnaires/Forms to be completed preoperatively in clinic with assistance from research study administrator: * Baseline sociodemographic and clinical variable data sheet (RSA) * EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS * Baseline disease status and treatment assessment questionnaire Questionnaires/Forms to be completed at first postoperative clinic visit: * EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS Questionnaires/Forms to be mailed to patients at ± 2 month window at the following time points 6,12,18,24, and 36 months following hepatectomy: * EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS * Post surgical follow up disease status and treatment assessment questionnaire * At 8 weeks following the mailing of the initial questionnaire package if no response has been received, research personnel will attempt to contact participants by phone.

06

What researchers measure

Primary outcomes

  1. changes in the quality of life (QoL)

    in patients at high risk of recurrence undergoing hepatectomy to assess health related quality of life (HRQoL) using the EORTC QLQ-C30, QLQ-LMC21 and the EuroQol EQ-5D-5L, in patients at high risk of recurrence undergoing hepatectomy for colorectal liver metastasis and to evaluate global and disease specific changes over time.

    Time frame: 3 years

07

Study locations

7 sites
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2015 (actual). Primary completion is estimated for Mar 2027, 144 months after the start.

Of 211 non-industry observational studies under Neoplasm Metastasis, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 172. This study's planned 144 months is above that.

Counting every sponsor, half of 242 studies reached it within 66 months; a quarter within 35 and three quarters within 172.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2015
First posted
Mar 26, 2015
StartActual
Mar 2015
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Apr 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02399995
Responsible party
Sponsor
First posted
Mar 26, 2015
Start date
Mar 2015
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Apr 14, 2026

Study contacts

Michael D'Angelica, MD
principal investigator · Memorial Sloan Kettering Cancer Center
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion